Apellis Pharmaceuticals (NASDAQ:APLS) has received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus target price of $35.25 for the company and are predicting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Apellis Pharmaceuticals an industry rank of 185 out of 265 based on the ratings given to its competitors.
Several research analysts recently commented on the company. JPMorgan Chase boosted their target price on Apellis Pharmaceuticals from $31.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, March 23rd. Zacks Investment Research raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, March 27th. B. Riley assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $27.00 target price for the company. Evercore ISI assumed coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They set an “outperform” rating for the company. Finally, Citigroup assumed coverage on Apellis Pharmaceuticals in a research note on Monday, December 4th. They set a “buy” rating and a $23.00 target price for the company.
Shares of NASDAQ APLS opened at $22.11 on Thursday. Apellis Pharmaceuticals has a twelve month low of $12.45 and a twelve month high of $27.53. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1,113.75 and a PE ratio of -6.02.
TRADEMARK VIOLATION NOTICE: This story was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.wkrb13.com/2018/04/01/brokerages-anticipate-apellis-pharmaceuticals-apls-to-post-0-27-earnings-per-share.html.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.